{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:23:58Z","timestamp":1782372238666,"version":"3.54.5"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>To clarify the efficacy of mineralocorticoid receptor antagonists (MRA) and renin-angiotensin system inhibitors\/angiotensin receptor neprilysin inhibitors (RASI\/ARNI) in heart failure with mildly reduced ejection fraction (HFmrEF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study assessed the association between these medications and outcomes in HFmrEF using data from the National Taiwan University Hospital-integrated Medical Database. The primary outcome was cardiovascular mortality\/heart failure hospitalization (HHF). Inverse probability of treatment weighting balanced baseline patient characteristics. The exposure of primary interest was use of MRA and use of RASI\/ARNI, while the non-user group was also likely to receive other heart failure medication treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 2,584 HFmrEF patients, 17% received MRA and 43% received RASI\/ARNI. Predictors of MRA use included older age, slightly higher ejection fraction, and lower NT-proBNP level. RASI\/ARNI use was predicted by higher BMI, lower NT-proBNP level, normal uric acid and potassium levels. MRA use was not associated with a lower risk of cardiovascular death [hazard ratio = 0.89, 95% confidence interval (CI): 0.78\u20131.02] or HHF (hazard ratio = 1.01, 95% CI: 0.94\u20131.09). Conversely, RASI\/\/ARNI use was linked to a lower risk of cardiovascular death (hazard ratio = 0.82, 95% CI: 0.71\u20130.94) but not HHF (hazard ratio = 0.995, 95% CI: 0.924\u20131.07). Landmark analysis showed no significant difference in outcomes for follow-up durations exceeding 2\u00a0years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MRA had a neutral effect on cardiovascular death and HHF, while RASI\/ARNI was associated with a lower risk of cardiovascular death. RASI\/ARNI may be more beneficial than MRA for HFmrEF patients. Regular re-evaluation is essential to adjust heart failure treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1507326","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T04:18:08Z","timestamp":1734063488000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative analysis of mineralocorticoid receptor antagonists and renin-angiotensin system inhibitors\/angiotensin receptor neprilysin inhibitor in heart failure with mildly reduced ejection fraction"],"prefix":"10.3389","volume":"15","author":[{"given":"Chia-Chen","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Te-Wei Kuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Chun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Fang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Tse","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho-Kai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1001\/archinte.165.7.742","article-title":"Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study","volume":"165","author":"Choi","year":"2005","journal-title":"Archives Intern. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/nejm198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure","volume":"316","author":"Consensus Trial Study Group","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jchf.2023.11.005","article-title":"Left ventricular ejection fraction and the future of heart failure phenotyping","volume":"12","author":"Dimond","year":"2024","journal-title":"JACC Heart Fail"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jchf.2019.08.017","article-title":"MRAs in elderly HF patients: individual patient-data meta-analysis of RALES, EMPHASIS-HF, and TOPCAT","volume":"7","author":"Ferreira","year":"2019","journal-title":"JACC Heart Fail"},{"key":"B5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.cardfail.2022.10.432","article-title":"Angiotensin receptor neprilysin inhibitor use and blood pressure lowering in patients with heart failure with reduced ejection fraction across the spectrum of kidney function: an analysis of the veterans administrative health system","volume":"29","author":"Gjyriqi","year":"2023","journal-title":"J. Card. Fail"},{"key":"B6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1001\/jamacardio.2016.1325","article-title":"Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction","volume":"1","author":"Kalogeropoulos","year":"2016","journal-title":"JAMA Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ekir.2019.05.018","article-title":"Hyperkalemia in real-world patients under continuous medical care in Japan","volume":"4","author":"Kashihara","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/ejhf.945","article-title":"A comprehensive population-based characterization of heart failure with mid-range ejection fraction","volume":"19","author":"Koh","year":"2017","journal-title":"Eur. J. Heart Fail"},{"key":"B10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jchf.2016.03.025","article-title":"Understanding heart failure with mid-range ejection fraction","volume":"4","author":"Lam","year":"2016","journal-title":"JACC Heart Fail"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1093\/eurheartj\/ehy005","article-title":"Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study","volume":"39","author":"Lam","year":"2018","journal-title":"Eur. Heart J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"Eur. J. Heart Fail"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/ejhf.824","article-title":"Recovered heart failure with reduced ejection fraction and outcomes: a prospective study","volume":"19","author":"Lup\u00f3n","year":"2017","journal-title":"Eur. J. Heart Fail"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e005652","DOI":"10.1161\/circheartfailure.118.005652","article-title":"Heart failure with preserved ejection fraction infrequently evolves toward a reduced phenotype in long-term survivors","volume":"12","author":"Lup\u00f3n","year":"2019","journal-title":"Circ. Heart Fail"},{"key":"B16","doi-asserted-by":"publisher","first-page":"08354","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 acc expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American college of cardiology solution set oversight committee","volume":"2","author":"Maddox","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/circresaha.121.318158","article-title":"Mechanisms and models in heart failure: a translational approach","volume":"128","author":"Mann","year":"2021","journal-title":"Circ. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"","journal-title":"Eur. Heart J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"","journal-title":"Eur. Heart J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejim.2022.04.006","article-title":"Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril\/valsartan. Position Paper of the Italian Society of Cardiology","volume":"102","author":"Perrone-Filardi","year":"2022","journal-title":"Eur. J. Intern Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/s0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"982372","DOI":"10.3389\/fphar.2022.982372","article-title":"Effects of sacubitril-valsartan on heart failure patients with mid-range ejection fractions: a systematic review and meta-analysis","volume":"13","author":"Qin","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","article-title":"Heart failure with mid-range or mildly reduced ejection fraction","volume":"19","author":"Savarese","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jchf.2018.11.019","article-title":"Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure","volume":"7","author":"Savarese","year":"2019","journal-title":"JACC Heart Fail"},{"key":"B27","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"","journal-title":"Eur. Heart J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"","journal-title":"Eur. Heart J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"B33","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/ehjcvp\/pvad036","article-title":"Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction","volume":"9","author":"Stolfo","year":"2023","journal-title":"Eur. Heart J. Cardiovasc Pharmacother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/ejhf.807","article-title":"Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study","volume":"19","author":"Tsuji","year":"","journal-title":"Eur. J. Heart Fail"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/ejhf.807","article-title":"Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study","volume":"19","author":"Tsuji","year":"","journal-title":"Eur. J. Heart Fail"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","article-title":"Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF","volume":"44","author":"Vaduganathan","year":"2023","journal-title":"Eur. Heart J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s40001-022-00945-z","article-title":"Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis","volume":"27","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1507326\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T04:18:11Z","timestamp":1734063491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1507326\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":37,"alternative-id":["10.3389\/fphar.2024.1507326"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1507326","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]},"article-number":"1507326"}}